Gilead inks deals to improve HIV treatment uptake in children
Justin Sullivan/Getty Images News

Gilead (NASDAQ:GILD) announced Thursday two public-private partnerships aimed at improving treatment and adherence among children with HIV in low- and middle-income countries.
In one partnership, the company will join hands with Penta ID Network, an organization focused on child health research, and the Clinton Health Access Initiative (CHAI) to develop a dispersible, fixed-dose combination of its HIV drugs, emtricitabine and tenofovir alafenamide (F/TAF).

The drug combo targeted at children with HIV in low- and middle-income countries will be developed by Gilead (GILD) and Penta ID, while CHAI, in partnership with global health agency Unitaid, will ensure its global access with two generic manufacturers.
In the other collaboration, the Foster City, California-based biotech has teamed up with Monell Chemical Senses Center, Eurofinsâ Translational Cell Models group, and CHAI. That partnership aims to develop pediatric versions of TAF and antiviral sofosbuvir (SOF) designed to address bitterness.


More on Gilead

Gilead raises stake in Arcus Biosciences
Gilead: An Evolving Biopharma Navigating Through Challenges And Opportunities